'Renal dose' dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery*
| Autor: | Samuel Samuel, Jean Pierre Yared, Norman J. Starr, Maged Argalious, Pablo Motta, A. Marc Gillinov, Farah Khandwala, C. Allen Bashour, Colleen G. Koch |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Resuscitation Heart disease Dopamine Renal function Critical Care and Intensive Care Medicine law.invention Postoperative Complications Risk Factors law Internal medicine Intensive care Atrial Fibrillation Cardiopulmonary bypass medicine Humans cardiovascular diseases Coronary Artery Bypass Ohio Retrospective Studies Cardiopulmonary Bypass business.industry Incidence Atrial fibrillation Middle Aged medicine.disease Cardiac surgery Logistic Models Atrial Flutter Anesthesia Multivariate Analysis cardiovascular system Cardiology Female Kidney Diseases business human activities Atrial flutter |
| Zdroj: | Critical Care Medicine. 33:1327-1332 |
| ISSN: | 0090-3493 |
| Popis: | "Renal dose" dopamine (rDA; 1-3 microg/kg per min) is administered to patients after cardiac surgery to preserve or improve renal function. Many of these patients develop new-onset postoperative atrial fibrillation or atrial flutter (pAF) that could be related to rDA administration. The objective of this investigation was to determine whether there was an association between rDA and new-onset pAF in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass (CABG).Research hospital.The study population consisted of 1,731 patients undergoing CABG.CABG with and without rDA.After approval by the institutional review board, a retrospective study using the Cardiothoracic Anesthesia Patient Registry was undertaken to determine the association between rDA and pAF in patients undergoing CABG. Patients with a documented history of atrial fibrillation, those who required inotrope use during or after surgery, and those having valve surgery were excluded.One-thousand seven-hundred thirty-one patients undergoing CABG during the period of January 1, 2000, through June 30, 2002, were the study population; of these, 15.0% (260/1,731) developed pAF. The incidence of pAF was 23.3 % (41/176) among patients who received rDA and 14.1% (219/1,555) among those who did not receive rDA. In the multivariable logistic regression model, patient age, gender, chronic obstructive pulmonary disease or asthma, and rDA were associated with pAF (p.01). Receipt of rDA increased the odds of developing pAF by 74%, independent of the effect of other variables.Renal-dose dopamine is associated with a 1.74 odds ratio of pAF developing after CABG. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|